Anteris Technologies Global Corp. (AVR) AI Stock Analysis

Anteris Technologies Global Corp., based in Toowong, Australia, develops and commercializes minimally invasive medical devices to treat heart valve diseases. Its primary product is the DurAVR transcatheter heart valve system, designed to mimic the performance of a healthy human aortic valve for severe aortic stenosis treatment. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds for surgical repair and aortic valve replacement. In addition, it develops the ComASUR delivery system, a physician-developed balloon-expandable delivery system with a reinforced steerable catheter for precise deflection through heart anatomy without damaging the aorta.

Annual revenue decreased from $5.8M in FY2021 to $1.9M in FY2025, reflecting a 5-year revenue CAGR of -18.9%. Gross margin swung from 32.7% in FY2021 to -16.6% in FY2025, while operating margin fell from -289.2% to -4908.2%. Net losses widened from -$17.2M in FY2021 to -$94.1M in FY2025, or -$2.56 per share, driven partly by research and development expense rising to $69.1M. Over the trailing twelve months, revenue was $2.2M, though the latest quarter ended June 30, 2026 recorded quarterly revenue growth of 63.3% year-over-year. Operating cash flow was -$77.8M in FY2025.

As of June 30, 2026, Anteris Technologies held $257.4M in cash and short-term investments and $3.3M in total debt, yielding net cash of $254.1M. Shareholders' equity stood at $251.4M out of $272.5M in total assets. The balance sheet carried a current ratio of 14.20 and a debt-to-equity ratio of 0.01. Free cash flow for FY2025 was -$79.8M, which included $2.0M in capital expenditures.

Anteris Technologies carries a market cap of $588.9M and an enterprise value of $489.1M. It trades at a price-to-sales multiple of 263.0x and an EV-to-revenue ratio of 218.1x, compared to a median price-to-sales of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 3.0x. Over the past year, the stock returned 22.0%, outperforming the S&P 500 (SPY) return of 16.8%. However, at $6.05 as of October 16, 2026, the stock traded 17.4% below its 200-day average.

Wall Street analysts hold 4 Strong Buy ratings and 1 Hold rating on Anteris Technologies, with no Sell ratings. The mean price target is $14.00, representing an upside of 131.4% from the last close of $6.05. For FY2026, analysts estimate an EPS of -$1.18 and revenue of $8.5M. For FY2027, five analysts project revenue of $14.1M, representing 65.2% growth, and EPS of -$1.15. The company delivered 0 EPS beats over the last 4 quarters. The next earnings date is November 11, 2026.

This page is an AI-written research summary of Anteris Technologies Global Corp. (AVR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AVR income statement, AVR balance sheet, AVR key metrics, AVR analyst forecast, AVR chart. See the AVR stock overview for the latest quote and news.